Moelis Earnings in Four Days: Shorts Covered, Street Cautious

Moelis & Company heads into its November 5 results with short sellers having already retreated sharply, options positioning only modestly defensive, and a Street consensus that has spent October trimming targets without abandoning the stock.

The most notable data shift since the two notes published earlier this week is that the short unwind has continued. Short interest now stands at 6.9% of the free float, down 14.3% on the week from levels above 8% in mid-October. That is a meaningful reduction in bearish positioning ahead of a catalyst. The ORTEX short score has fallen alongside it, dropping from 52.8 on October 16 to 48.9 on October 29, now fractionally below the neutral midpoint. The lending market confirms there is no mechanical squeeze pressure: availability runs at roughly 1,086%, meaning more than ten shares are sitting ready to lend for every one currently borrowed. Borrow costs remain negligible at 0.45%. Short sellers covering before earnings, with no distress in the borrow pool, is a cleaner read of conviction declining than of any tactical squeeze.

Options positioning is mildly more cautious than usual, though it has not shifted materially since the October 28 note. The put/call ratio is 0.56 against a 20-day average of 0.47, a z-score of 0.77. That is above average but well within normal territory, nothing like the defensive extremes the ratio has hit this year (the 52-week high is 1.24). The stock gained 7.4% on the week before Friday's 2.3% pullback to $58.59. Among close peers, EVR led with a 15.3% weekly gain, PWP added 19%, and PJT rose 6.2%. LAZ was more modest at 3.1%. The sector has broadly re-rated higher into what looks like positioning for an advisory cycle recovery, with Moelis participating but not leading.

The Street has spent October marking down targets without abandoning the bullish case. JP Morgan maintained its Neutral rating last week while cutting the target to $68 from $70. Goldman Sachs, which also holds Neutral, trimmed to $62 from $71 earlier in October. Morgan Stanley holds Overweight but cut to $77 from $85 earlier in the month. UBS upgraded from Sell to Neutral, lifting its target to $59. The mean target across the Street is $67.30, about 15% above the current price. The analyst recommendation divergence factor score ranks in the 98th percentile of Moelis's universe, suggesting the gap between the most bullish and most bearish views on the stock is unusually wide right now. The bull case rests on the record pipeline and the 41% sequential revenue jump reported last quarter. Bears point to slippage in the sponsor backlog and the risk that M&A volumes disappoint if the macro environment softens. The price-to-book multiple has expanded roughly 0.7 points over the past 30 days to 7.9x, reflecting the October re-rating in the stock.

Wikipedia traffic data from the Wikimedia Foundation shows retail attention running at a z-score of 3.3 against Moelis's own 90-day history, a notably elevated reading. This dataset has not been measured to lead the company's reported figures, so it is colour rather than signal. It does suggest the name is drawing more attention than usual heading into the print.

The institutional register shows BlackRock added 647,000 shares in the quarter ending September 30, lifting its stake to 12.2% of shares. Columbia Management and Charles Schwab both added positions in the same period. Kayne Anderson Rudnick and Wasatch Advisors have been reducing, and both have dropped below the 5% threshold since their last 13G filings, consistent with the activist register showing no 13D holders. There are no open-market insider purchases in the recent trade data; the September filings are all small director stock grants, not discretionary buys.

With earnings four days away, the question is whether the pipeline language from Q3 translates into Q4 guidance that justifies the October re-rating, or whether target cuts from four major banks in the past month prove more prescient.